explore -WSS

explore

author：entertainment 2025-10-02 17:23:05 - browse：116

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Test for long Covid? Researchers find new clue in blood samples

hotspot

WSS

What we need to know about Arena Bioworks

Biotech venture capitalists face new demands from investors

Biotech venture capitalists face new demands from investors

Humana cuts profit projections as Medicare Advantage costs soar

EU regulator recommends expanding Mounjaro approval to obesity

How digital therapeutics firms are pivoting after Pear's bankruptcy

hotspot

explore

focus

23andMe had bad news about my health. I wish a person had delivered it

Francis Collins on trust in science and how Covid communications failed

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

How one medical school became remarkably diverse

Why doctors need education on FDA device approval process

Virginia high school admissions case could be legal follow

The surgeon had a dilemma only a Nazi medical text could resolve

After affirmative action ruling, medical educators look to 'holistic review'

Copay coupons to count toward deductibles, after Biden court move

hotspot

A $475,000 price tag for a new cancer drug: crazy or meh?

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Independent physicians launch a new lobbying group

Research misconduct: Proposed new rules face resistance

A $475,000 price tag for a new cancer drug: crazy or meh?

New brain studies show LSD's effects on the brain in full color

focus

hotspot

knowledge

explore